CryoCor submits PMA for atrial flutter
This article was originally published in The Gray Sheet
Executive Summary
Safety and efficacy data from a 160-patient, 22-site clinical trial are submitted as final module to FDA for CryoBlater. The submission follows the opening of the firm's IPO in mid-July; funds from the public offering will be used to offset costs incurred from the trial. CryoCor also is preparing for an atrial fibrillation indication for its cryoablation device (1"The Gray Sheet" July 18, 2005, p. 8)...